Stocks · News reference
Anixa Biosciences Q3 EPS $(0.08) Beats $(0.09) Estimate, Sales $0.00, Same YoY
Anixa Biosciences (NASDAQ:ANIX) reported quarterly losses of $(0.08) per share which beat the analyst consensus estimate of $(0.09) by 11.11 percent. This is a 14.29 percent decrease over losses of $(0.07) per share
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
Anixa Biosciences Issued Notice Of Acceptance From IP Australia For Its Breast Cancer Vaccine Technology
Anixa Biosciences, Inc. ("Anixa" or the "Company") (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer, today announced that IP Australia has issued a Notice of
Anixa Biosciences Doses First Participant In Fifth Group Of Its Phase 1 Clinical Study Of CAR-T/CER-T Therapy For Recurrent Ovarian Cancer